Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Rine

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|August 21, 2019
Assessing Patient Participation Burden Based on Protocol Design CharacteristicsKenneth Getz, Venkat Sethuraman, Jessica Rine, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
Assessing Patient Participation Burden Based on Protocol Design CharacteristicsKenneth Getz, Venkat Sethuraman, Jessica Rine, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2018
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated MyelomaVincent L Hansen, Morton Coleman, Stephanie Elkins, et al.
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|August 21, 2019
Assessing Patient Participation Burden Based on Protocol Design CharacteristicsKenneth Getz, Venkat Sethuraman, Jessica Rine, et al.
Therapeutic Innovation & Regulatory Science|December 10, 2020
Assessing Patient Participation Burden Based on Protocol Design CharacteristicsKenneth Getz, Venkat Sethuraman, Jessica Rine, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2018
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated MyelomaVincent L Hansen, Morton Coleman, Stephanie Elkins, et al.
British Journal of Haematology|May 25, 2013
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosisDaniel J DeAngelo, Ruben A Mesa, Warren Fiskus, et al.
Pageof 1